WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

Novartis taps Antares in small molecule discovery pact with $105M upfront

Antares Therapeutics inks $105M upfront deal with Novartis to discover small molecules against undruggable cancer targets, with up to $1.8B in milestones.

Raccontata daendpoints.newsbenzinga.com

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
endpoints.newsStai leggendo19 h fa

Novartis taps Antares in small molecule discovery pact with $105M upfront

Antares Therapeutics inks $105M upfront deal with Novartis to discover small molecules against undruggable cancer targets, with up to $1.8B in milestones.

originale
benzinga.com18 h fa

Novartis, Antares Partner To Pursue Undruggable Cancer Targets In $1.9 Billion Deal - Novartis (NYSE:NVS)

Antares inks Novartis collaboration worth up to $1.9 billion to develop therapies targeting hard-to-treat cancers.

Leggi questa versione → originale

Timeline cronologica

  1. mercoledì 24 giugno 2026·endpoints.news

    Novartis taps Antares in small molecule discovery pact with $105M upfront

    Antares Therapeutics inks $105M upfront deal with Novartis to discover small molecules against undruggable cancer targets, with up to $1.8B in milestones.

  2. mercoledì 24 giugno 2026·benzinga.com

    Novartis, Antares Partner To Pursue Undruggable Cancer Targets In $1.9 Billion Deal - Novartis (NYSE:NVS)

    Antares inks Novartis collaboration worth up to $1.9 billion to develop therapies targeting hard-to-treat cancers.